Skip to main content
SpringerLink
Log in

Prasugrel and Ticagrelor: the Romulus and Remus of Antiplatelet Therapy?

  • Commentary
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

The Original Article was published on 27 April 2019

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update. Circulation. 2015;131:e29–322.

    PubMed  Google Scholar 

  2. Hamm CW, Bassand J-P, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999–3054.

    Article  PubMed  Google Scholar 

  3. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213–60.

    Article  PubMed  Google Scholar 

  4. Qaderdan K, Ishak M, Heestermans AACM, de Vrey E, Jukema JW, Voskuil M, et al. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: optimization of antiplatelet treatment in patients 70 years and older—rationale and design of the POPular AGE study. Am Heart J. 2015;170(981–5):e1.

    Google Scholar 

  5. Han Y, Xu B, Xu K, Guan C, Jing Q, Zheng Q, et al. Six versus 12 months of dual antiplatelet therapy after implantation of biodegradable polymer sirolimus-eluting stent. Circ Cardiovasc Interv. 2016;9:e003145.

    Article  CAS  PubMed  Google Scholar 

  6. Khayata M, Gabra JN, Nasser MF, Litman GI, Bhakta S, Raina R. Comparison of clopidogrel with prasugrel and ticagrelor in patients with acute coronary syndrome: clinical outcomes from the national cardiovascular database ACTION Registry. Cardiol Res. 2017;8:105–10.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Cattaneo M. Aspirin and Clopidogrel. Arterioscler Thromb Vasc Biol. 2004;24:1980–7.

    Article  CAS  PubMed  Google Scholar 

  8. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2429–36.

    Article  CAS  PubMed  Google Scholar 

  9. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363–75.

    Article  CAS  PubMed  Google Scholar 

  10. Angiolillo DJ, Bates ER, Bass TA. Clinical profile of prasugrel, a novel thienopyridine. Am Heart J. 2008;156:16S–22S.

    Article  CAS  Google Scholar 

  11. Bonello L, Lemesle G, Laine M. Ticagrelor Is the Best Antiplatelet Agent for Pretreatment in Patients With ACS. American College of Cardiology—Latest in Cardiology 2016. https://www.acc.org/latest-in-cardiology/articles/2016/06/13/10/01/ticagrelor-is-the-best-antiplatelet-agent-for-pretreatment-in-patients-with-acs. Accessed 18 Feb 2019.

  12. Bundhun PK, Shi J-X, Huang F. Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials. BMC Pharmacol Toxicol. 2017;18:80.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Sakurai R, Burazor I, Bonneau HN, Kaneda H. Head-to-head comparison of prasugrel versus ticagrelor in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. J Interv Cardiol. 2017;30:457–64.

    Article  PubMed  Google Scholar 

  14. De Fillippo O, Cortese M, D´Ascenzo F, Raposeiras Roubin S, Abu-Assi E, Kinnaird T, et al. Real world data of Prasugrel vs Ticagrelor in acute 1 myocardial infarction: results from the RENAMI registry. Am J Cardiovasc Drugs. 2019. https://doi.org/10.1007/s40256-019-00339-3.

    Article  PubMed  Google Scholar 

  15. Biondi-Zoccai G, Lotrionte M, Agostoni P, Abbate A, Romagnoli E, Sangiorgi G, et al. Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. Int J Cardiol. 2011;150:325–31.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy

    Vittoria Cammisotto, Giuseppe Biondi-Zoccai & Giacomo Frati

  2. Mediterranea – Cardiocentro, Napoli, Italy

    Giuseppe Biondi-Zoccai

  3. IRCCS NEUROMED, Pozzilli, Italy

    Giacomo Frati

  4. Unità Operativa di Interventistica Cardiovascolare, Presidio Ospedaliero Pineta Grande, Castel Volturno, Italy

    Arturo Giordano

Authors
  1. Vittoria Cammisotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Biondi-Zoccai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giacomo Frati
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arturo Giordano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Biondi-Zoccai.

Ethics declarations

Funding

No sources of funding were used to conduct this study or prepare this manuscript.

Conflicts of interest

Prof. Biondi-Zoccai has consulted for Abbott Vascular and Bayer. Vittoria Cammisotto, Giacomo Frati, and Arturo Giordano have no conflicts of interest that are directly relevant to the content of this article.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cammisotto, V., Biondi-Zoccai, G., Frati, G. et al. Prasugrel and Ticagrelor: the Romulus and Remus of Antiplatelet Therapy?. Am J Cardiovasc Drugs 19, 377–379 (2019). https://doi.org/10.1007/s40256-019-00340-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-019-00340-w

Search

Navigation